Comedications, comorbidities, and survival in breast cancer patients: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAL INtEraction) study

Département Information Systems et Operations Management

Intervenant: Anne-Sophie Hamy-Petit and Elise Dumas (Institut Curie)

Salle Bernard Ramanantsoa

Abstract
Breast cancer (BC) is the most frequent cancer among women and the leading cause of cancer death in women worldwide. Its incidence increases with age, as does the incidence of many other chronic diseases, such as hypertension, diabetes, or dyslipidemia. Between 30% and 70% of BC patients suffer from pre-existing chronic conditions at BC diagnosis, namely comorbidities and more than half of patients take comedications – i.e. chronically used non-cancer treatments. Epidemiological evidence has reported that several comedications may impact BC risk, BC recurrence, and overall survival. The ADRENALINE project (Atlas of DRugs, comorbiditiEs and caNcer treAtment survivaL INtEraction) aims at analyzing at a very large scale, using data from the French national health insurance system (Système National des Données de Santé, SNDS), the impact of the use of all comedications at BC diagnosis on survival. After applying robust state-of-the-art causal inference methods to a large cohort of 235,368 French BC patients, we identified 39 molecules with a significant deleterious or protective association with survival. The results are available on an interactive online tool, enabling to explore the distribution of comorbidities, comedications, their co-occurrence, and ultimately the association between comedications and survival (https://adrenaline.curie.fr).